Overview

Apremilast

CAS

608141-41-9

Status

Development

Apremilast is a phthalimide derivative that acts as a phosphodiesterase inhibitor (PDE-4 inhibitor). As a result, fewer inflammatory factors (TNF-α) are released. The substance is used for medium to severe, chronic plaque psoriasis and psoriasisarthritis. It was approved in the US in 2014 and the EU in 2015.

Description

Formula

C22H24N2O7S

Molecular weight

460.00 g/mol

Molecular size

small

Controlled Substance

no

Precursor

no

Indications

Immunosuppressants drugs

Your Contact

Marius Hang

Marius Hang

International Division
Director API Export

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
  • Disclaimer

    The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

    No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.

Complementary Services

Share this page